VOR Vor Biopharma Inc. Common Stock

XNAS 18.64 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

VOR $18.64 —
Key stats
$18.64
52-Week Range
$6.50 – $30.40
YTD
+60.14%
IV Rank (30D)
20.48
Straddle Price
$3.80
P/C Vol Ratio
0.84
Market Cap
$1.1B
Open
$18.06
Day Range
$18.00 – $18.80
Volume
40,081
Prev Close
$18.04
Fair Value
-4.4% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.10%
Beta vs SPY1.75
Cost of Equity (CAPM)14.75% (VRP-adj)
WACC14.81%
Volatility Risk Premium+109.2pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-313.6%
Book / Price-50.7%
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$21.43 (Market Anchor value)
SMA 20 / Bollinger Mid$18.93
Bollinger Width / SMA2098.9% (drives anchor stability)
Net Debt$-0.2B
Market Cap$0B
Peers used for multiples: ATAI, ERAS, MBX, ORKA, RVMD, SYRE, TRAX (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$17.88
Deviation
-4.4%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0% median 9.9× · 4 peers
Peer P/S n/a 0%
Market Anchor (SMA50) $21.43 0% stability 0% (BB-width)
Options Expected (B-L 30d) $17.88 100% 11 strikes · skew +0.07
As of 2026-10-20 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$1.1B
Employees
76
List Date
2021-02-05
CIK
0001817229
Next Earnings
2026-11-12
EPS Forecast
($0.81) (4 est.)
Headquarters
Boston, MA
Homepage
https://www.vorbio.com

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---32.54%-22.04%3.14%26.79%11.68%-2.59%
Feb19.89%4.63%5.48%-2.13%-19.40%20.72%4.87%
Mar-10.21%-31.67%-2.36%4.41%-24.63%12.20%-8.71%
Apr-27.33%-9.34%-14.91%-21.82%9.53%-17.60%-13.58%
May-27.32%-28.64%9.56%-23.73%-69.76%8.09%-21.97%
Jun-9.25%23.02%-34.81%-30.07%591.42%26.36%94.44%
Jul-37.59%-4.16%2.03%-6.12%44.76%15.13%2.34%
Aug17.99%5.34%-21.14%-7.00%-6.19%5.00%-1.00%
Sep5.80%-25.05%-20.60%-16.00%19.41%-15.72%-8.69%
Oct1.88%22.39%-6.39%31.63%-38.59%3.49%*2.40%
Nov-29.68%-1.92%11.78%3.39%-62.83%---15.85%
Dec2.65%40.00%17.19%27.73%70.31%--31.58%
Total-70.44%-51.19%-61.77%-43.97%11.20%79.50%-22.78%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $18.76
SMA 50: $21.34
SMA 200: $17.08
Current: $18.69
EMA 12: $18.87
EMA 26: $19.57
MACD: -0.7050 | Signal: 0.0623
BEARISH
ADX (14): 11.65
RANGE
+DI: 17.77
−DI: 22.00

Momentum Oscillators

RSI (14): 43.60
NEUTRAL
Stoch %K: 20.84
Stoch %D: 30.00
Williams %R: -65.59

Volume & Volatility

BB Upper: $19.83
BB Lower: $17.69
NEUTRAL
OBV: 70,179,452
Vol SMA 20: 982,826
Vol ROC: -91.65%
ATR: $1.22
True Range: $0.80
HV 20: 68.1%
HV 30: 62.2%
HV 60: 61.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-21T00:00:00 – 2026-10-19T00:00:00
AI Analysis

LLM Stock Analysis Report: VOR

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Bullish MACD signal with a significant histogram reading, indicating strong momentum
  • Recent positive news sentiment from the Telitacicept Phase 3 clinical study outcome

Primary risks:

  • High volatility and beta relative to the market, making it more sensitive to changes in market conditions
  • Bearish put/call volume ratio and options market expectation of a $4.75 move by expiration, indicating potential downside risk

Investment thesis: Vor Bio's recent progress with its clinical study outcome could lead to increased investor optimism, driving the stock price higher. However, the high volatility and beta levels may increase the risk of significant price movements.

Recent news sentiment impact: The positive sentiment from the Telitacicept Phase 3 clinical study outcome has contributed to the bullish tone in the analysis.

Technical Analysis

Trend Direction:

  • Short-term: Uptrend
  • Medium-term: Uptrend
  • Long-term: Uptrend

Support/Resistance Levels:

  • Upper Bollinger Band: $24.86 (resistance)
  • Middle Line: $22.52 (support)
  • Lower Bollinger Band: $20.18 (support)

Momentum Signals:

  • RSI: 56.83 (neutral) - not indicating an overbought or oversold condition
  • MACD: Bullish signal with a significant histogram reading, indicating strong momentum
  • Bollinger Bands: Neutral signal, indicating no clear direction

Volume Analysis:

  • Volume SMA 20: 772083.83 (increasing trend)
  • On-Balance Volume (OBV): 77169144.85 (neutral)
  • Volume Rate of Change: -60.36% (decreasing trend)

News & Sentiment Analysis

Recent Headlines Summary:

  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire Inc., 2026-07-02, NEUTRAL)
  • Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China (GlobeNewswire Inc., 2025-11-08, POSITIVE)

Sentiment Assessment:

  • Aggregate sentiment: Positive

Catalyst Identification:

  • Upcoming earnings release
  • Regulatory updates on Telitacicept's clinical trial progress

Market Narrative:

  • The positive news from the Telitacicept Phase 3 clinical study outcome has contributed to the bullish tone in the market, aligning with the technical analysis.

Risk & Volatility Assessment

Risk & Volatility Assessment:

  • Beta: 1.48 (high risk relative to the market)
  • Volatility Regime: High
  • Options Market Signals:
    • IV Rank: 22.6% (Low) - shows historically low volatility
    • Current IV: 101.9%
    • Expected Move: $4.75 (25 DTE), 7-DTE: $4.75

Downside Protection:

  • Support levels: Middle Line ($22.52), Lower Bollinger Band ($20.18)

Market Context & Positioning

Market Context & Positioning:

  • Sector Performance: Vor Bio's stock is outperforming the sector average
  • Institutional Activity: Increasing institutional interest with a high volume trend
  • Correlation Analysis:
    • R-squared interpretation: 0.17 (low correlation) - indicating the stock moves relatively independently of the market

Relative Valuation:

  • Position within trading range: Bullish, as the stock is above its middle line and Bollinger Bands are tight.

Key Levels & Action Items

Critical Price Levels:

  • Support levels: Middle Line ($22.52), Lower Bollinger Band ($20.18)
  • Resistance levels: Upper Bollinger Band ($24.86)

Breakout/Breakdown Levels:

  • Technical levels that could trigger significant moves: $23.50 (breakout) and $21.50 (breakdown)

Time-Sensitive Catalysts:

  • Upcoming earnings release
  • Regulatory updates on Telitacicept's clinical trial progress

Risk Management:

  • Stop-loss levels: $20.18 (Lower Bollinger Band)
  • Position sizing considerations: Consider reducing position size due to high volatility and beta levels.

By analyzing the technical indicators, news sentiment, and risk metrics, it appears that Vor Bio's stock is in a bullish trend, driven by recent positive news from its clinical study outcome. However, the high volatility and beta levels increase the risk of significant price movements. It is essential to monitor the support and resistance levels, as well as the upcoming earnings release and regulatory updates, to adjust the investment thesis accordingly.

Generated
Earnings History
1 of 1 under expected move
Avg Expected Move
37.63%
Avg Actual Move
4.66%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-01-12 unknown 37.63% 4.66% 0.12x Within

Earnings calendar: this week’s reports with expected vs actual moves →

VOR Options Activity & IV Rank

VOR IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 98.2%
7-DTE IV: —
Expected Move: $3.80
7-DTE Move: $3.80
Days to Exp: 31 (2026-11-20)

Options Flow

Call Volume: 341
Put Volume: 285
P/C Volume: 0.836
NEUTRAL
Call OI: 544
Put OI: 286
P/C OI: 0.526
Total OI: 830

ATM Options Pricing

ATM Call: $2.27
ATM Put: $1.52
Call %: 12.2%
Put %: 8.2%

Chain Summary

Chain Volume: 1,626
Chain OI: 10,572
Last Updated: 10/20/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 95th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
95%
vs own history
GEX tilt
+0.80
OI-weighted, today
Vanna tilt
+0.96
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.96: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 7 ATM contracts, 2k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 86.7% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)20.5LowOct 20
Straddle Price (30 DTE)$3.80Oct 20
Beta Analysis

Risk Metrics

Beta: 1.7149
Alpha: -10.40%
Correlation: 0.2058
R-Squared: 4.2%
Stock Volatility: 105.8%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own VOR
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$7.9M
0.01%
#1759 of 3716+65.5%13F
Citadel Hedge fund
Ken Griffin
$3.0M
0.00%
#2535 of 6285+7.8%13F
Renaissance Technologies Hedge fund
Jim Simons
$608K
0.00%
#2533 of 3138-74.4%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

VOR Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 16,457,194 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

109 filers49,265,604 shares$902.89M value299.36% of float
# Filer Shares Value % of Total % of Float Period
1 TCG Crossover Management, LLC 5,673,078 $104.44M 11.57% 34.47% 2026-06-30
2 FMR LLC Custodian 4,932,149 $90.80M 10.06% 29.97% 2026-06-30
3 FCPM III SERVICES B.V. 4,117,354 $75.80M 8.40% 25.02% 2026-06-30
4 BlackRock, Inc. Custodian 3,468,107 $63.85M 7.07% 21.07% 2026-06-30
5 Venrock Adviser, LLC 3,041,719 $56.00M 6.20% 18.48% 2026-06-30
6 State Street Corp 2,616,336 $48.17M 5.33% 15.90% 2026-06-30
7 Frazier Life Sciences Management, L.P. 2,543,939 $46.83M 5.19% 15.46% 2026-06-30
8 RA CAPITAL MANAGEMENT, L.P. 2,402,095 $44.22M 4.90% 14.60% 2026-06-30
9 Vanguard Capital Management LLC 2,084,328 $38.37M 4.25% 12.67% 2026-06-30
10 Caligan Partners LP 1,925,066 $35.44M 3.93% 11.70% 2026-06-30
11 Paradigm Biocapital Advisors LP 1,750,000 $32.22M 3.57% 10.63% 2026-06-30
12 GREAT POINT PARTNERS LLC 1,700,000 $31.30M 3.47% 10.33% 2026-06-30
13 Geode Capital Management, LLC Custodian 1,062,469 $19.56M 2.17% 6.46% 2026-06-30
14 NEXTBio Capital Management LP 889,164 $16.37M 1.81% 5.40% 2026-06-30
15 Nantahala Capital Management, LLC 845,000 $15.56M 1.72% 5.13% 2026-06-30
16 ADAR1 Capital Management, LLC 680,626 $12.53M 1.39% 4.14% 2026-06-30
17 Logos Global Management LP 650,000 $11.97M 1.33% 3.95% 2026-06-30
18 Rosalind Advisors, Inc. 648,600 $11.94M 1.32% 3.94% 2026-06-30
19 NAN FUNG TRINITY (HK) Ltd 646,550 $11.90M 1.32% 3.93% 2026-06-30
20 BRAIDWELL LP 573,104 $10.55M 1.17% 3.48% 2026-06-30
21 BOOTHBAY FUND MANAGEMENT, LLC 558,702 $10.29M 1.14% 3.39% 2026-06-30
22 Vanguard Group Inc Custodian 770,250 $10.07M 1.12% 4.68% 2025-12-31
23 UBS Group AG Custodian 493,278 $9.08M 1.01% 3.00% 2026-06-30
24 Millennium Management LLC Custodian 428,067 $7.88M 0.87% 2.60% 2026-06-30
25 SPHERA FUNDS MANAGEMENT LTD. 416,417 $7.67M 0.85% 2.53% 2026-06-30
1 filers$11.05K notional
# Filer Notional Value % of Total Period
1 GROUP ONE TRADING LLC Custodian $11.05K 100.00% 2026-06-30
1 filers$1.19M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $1.19M 100.00% 2026-06-30

VOR Insider Trading (Form 4)

Latest: 2026-10-05
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-05 RA Capital Healthcare Fund LP 10%+ Owner Exer (M) +2,000 $12.80 $25.6K EDGAR
2026-08-26 RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Exer (M) +6,000 $3.74 $22.4K EDGAR
2026-07-21 Peter Kolchinsky 10%+ Owner Mixed +8,399,148 $0.00 -$27 EDGAR
2026-07-09 David Zaccardelli Director Grant (A) +42,658 opt — EDGAR
2026-06-12 Daniella Beckman Director Grant (A) +53,283 opt — EDGAR
2026-06-12 Alexander Cumbo Director Grant (A) +56,345 opt — EDGAR
2026-06-12 Erez Kalir Director Grant (A) +57,162 opt — EDGAR
2026-06-12 Andrew David Levin Director Grant (A) +57,162 opt — EDGAR
2026-06-12 Michel Detheux Director Grant (A) +57,162 opt — EDGAR
2026-06-12 Fouad Namouni Director Grant (A) +56,549 opt — EDGAR
2026-06-12 Wouter Joustra Director Grant (A) +57,162 opt — EDGAR
2026-06-12 RA Capital Healthcare Fund LP Director Grant (A) +228,648 opt — EDGAR
2026-04-24 RA Capital Healthcare Fund LP Director Sell (S) −660,600 $15.77 -$10.42M EDGAR
2026-04-21 Peter Kolchinsky Director Sell (S) −2,521,496 $16.14 -$40.70M EDGAR
2026-04-15 RA Capital Healthcare Fund LP Director Sell (S) −2,951,956 $16.10 -$47.53M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

VOR Insider Holdings

13 insiders · @ $18.69
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Peter Kolchinsky Director 4,501,882 $84.14M -$140.27M 7 2026-07-21
2 Rajeev M. Shah Director 3,936,436 $73.57M -$82.92M 4 2026-04-10
3 RA Capital Nexus Fund, L.P. Director 1,891,036 $35.34M $0 1 2024-12-30
4 Reid Hoffman 10%+ Owner 1,333,792 $24.93M -$28.14M 7 2025-10-15
5 Reprogrammed Interchange LLC 10%+ Owner 1,178,725 $22.03M -$27.22M 6 2025-10-21
6 Qing Che Zuraw Chief Development Officer 46,854 $875.7K $0 2 2025-12-09
7 Robert Ang PRESIDENT AND CEO 45,566 $851.6K $0 23 2025-05-07
8 Tirtha Chakraborty Chief Sci Off & Head Tech Ops 10,871 $203.2K $0 24 2025-05-07
9 Eyal C. Attar CHIEF MEDICAL OFFICER 6,331 $118.3K -$39.9K 19 2025-02-18
10 Han Wook Choi Chief Financial Officer 2,564 $47.9K $0 3 2025-05-02
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

VOR Proposed Insider Sales (Form 144)

Latest: 2025-10-20
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-10-20 RA Capital Nexus Fund, L.P. Director, 10% Stockholder 15,104 $444.5K 2025-10-20 BTIG, LLC — EDGAR
2025-10-20 RA Capital Healthcare Fund LP Director, 10% Stockholder 76,919 $2.26M 2025-10-20 BTIG, LLC — EDGAR
2025-10-17 RA Capital Nexus Fund, L.P. Director, 10% Stockholder 42,816 $1.24M 2025-10-17 BTIG, LLC — EDGAR
2025-10-17 RA Capital Healthcare Fund LP Director, 10% Stockholder 218,043 $6.32M 2025-10-17 BTIG, LLC — EDGAR
2025-10-16 RA Capital Nexus Fund, L.P. Director, 10% Stockholder 24,916 $724.1K 2025-10-16 BTIG, LLC — EDGAR
2025-10-16 RA Capital Healthcare Fund LP Director, 10% Stockholder 126,887 $3.69M 2025-10-16 BTIG, LLC — EDGAR
2025-10-15 RA Capital Nexus Fund, L.P. Director, 10% Stockholder 8,430 $254.8K 2025-10-15 BTIG, LLC — EDGAR
2025-10-15 RA Capital Healthcare Fund LP Director, 10% Stockholder 42,933 $1.30M 2025-10-15 BTIG, LLC — EDGAR
2025-09-03 Reprogrammed Interchange LLC 10% Stockholder 23,000,000 $46.12M 2025-09-03 Audrey skillern — EDGAR
2025-08-11 Robert Ang Officer, Director 18,382 $36.4K 2025-08-11 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
36 ETFs hold VOR
25 shown · $102.86M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $29.6M — 2026-09-30
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.21% $20.7M $9.9B 2026-10-16
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $17.9M $74.8B 2026-10-16
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $8.3M — 2026-09-30
5 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.07% $4.6M $6.5B 2026-10-16
6 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.03% $4.4M $13.3B 2026-10-16
7 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $4.3M — 2026-09-30
8 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.16% $2.4M — 2026-07-31
9 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.17% $2.2M $1.2B 2026-10-16
10 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $2.0M $13.5B 2026-10-16
11 VHT Vanguard Health Care ETF Vanguard 0.01% $1.3M — 2026-09-30
12 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $1.2M $96.3B 2026-10-16
13 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.15% $816,200 — 2026-10-19
14 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.03% $550,038 — 2026-09-30
15 OMFS Invesco Russell 2000 Dynamic Multifactor ETF Invesco 0.20% $514,648 — 2026-10-18
16 BBC Virtus Biotech Clinical Trials Etf Nport 0.99% $457,771 — 2026-07-31
17 RSSL Global X Russell 2000 ETF Global X 0.02% $334,209 — 2026-10-19
18 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $324,801 — 2026-07-31
19 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $250,815 $10.7B 2026-10-16
20 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $237,689 $20.4B 2026-10-16
21 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.02% $210,452 — 2026-09-30
22 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.01% $197,320 $3.8B 2026-10-16
23 IBBQ Invesco Nasdaq Biotechnology ETF Invesco 0.07% $80,432 — 2026-10-18
24 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $64,681 — 2026-09-30
25 WSML iShares MSCI World Small-Cap ETF iShares (BlackRock) 0.01% $44,949 $652.0M 2026-10-16
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-70.33
TTM Revenue
—
TTM Net Income
$-883.08M
TTM Op. Cash Flow
$-149.89M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-219.59M$-5.11$-38.25M
Q4 '252025-12-31—$1.72B$307.61$-22.80M
Q3 '252025-09-30—$-812.68M$-121.63$-53.66M
Q2 '252025-06-30—$-1.57B$-251.20$-35.18M
Q1 '252025-03-31—$-32.49M$-5.21$-31.07M
Q4 '242024-12-31—$-30.71M$-8.78$-24.06M
Q3 '242024-09-30—$-27.56M$-8.05$-23.29M
Q2 '242024-06-30—$-27.84M$-8.20$-21.85M
Q1 '242024-03-31—$-30.80M$-9.00$-30.46M
Q4 '232023-12-31—$-26.26M$-7.60$-24.03M
Q3 '232023-09-30—$-33.19M$-9.80$-27.90M
Q2 '232023-06-30—$-29.98M$-9.00$-24.10M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-13
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
—
ROA
-174.3%
Div Yield
0.00%
FCF Yield
-48.73%
Debt/Equity
—
Current Ratio
—
Market Cap
$307.58M
as of 2026-10-20
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
7.81M
SI % of Float
18.50%
Days to Cover
4.34
Short Vol Ratio
48.0%
Free Float
42.24M
Float %
71.4%
Short interest 2026-09-30 • Short volume 2026-10-19 • Float 2026-09-22